Skip to main content

Table 5 Sleep diary data

From: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

  PEA Placebo
Baseline Week 4 Week 8 Baseline Week 4 Week 8
Sleep time (hrs) 6.1 ± 1.5 6.7 ± 1.4 6.7 ± 1.3 6.1 ± 1.5 6.5 ± 1.3 6.5 ± 1.5
Sleep Latencya (min) 42.8 ± 42.2 26.8 ± 26.3* 23.4 ± 23.1* 36.2 ± 40.5 34.2 ± 40.5 30.3 ± 39.2
Interruptions (n) 3.3 ± 2.1 3.0 ± 2.3 3.3 ± 3.0 3.9 ± 3.8 3.0 ± 3.0 2.9 ± 2.8
Interruptions (min) 41.0 ± 39.3 29.9 ± 30.1 35.0 ± 34.8 35.3 ± 32.0 31.6 ± 41.5 32.6 ± 42.7
  1. N.B. Data presented as mean ± standard deviation; * = significant difference between groups; a sleep latency data for participants reporting > 10 min at baseline (n = 78); PEA Palmitoylethanolamide